These medications, such as liraglutide, semaglutide, and tirzepatide, have shown significant results in lowering HbA1c levels and promoting weight loss, which is particularly beneficial for patients with coexisting diabetes and obesity
At Cape Fear Physical Medicine and Rehab, we understand that managing chronic conditions like obesity often requires a comprehensive approach
GLP-1 drugs are often not covered by private insurance
GLP-1R agonists such as semaglutide, tirzepatide, and mazdutide not only promote insulin secretion, suppress appetite, and delay gastric emptying, thereby effectively reducing body weight, but also help improve lipid profiles and reduce the risk of cardiovascular diseases
Real-World Results In clinical studies: Wegovy users lost an average of 15% body weight over 68 weeks Mounjaro users lost up to 20% body weight over 72 weeks Thats incredible, but its not one-month data
Future Directions and Potential Applications The future of Retatrutide is bright, with ongoing research exploring its potential role in long-term obesity treatment plans and its benefits in managing other health conditions